Search hospitals > Montana > Great Falls
Benefis Healthcare- Sletten Cancer Institute
Claim this profileGreat Falls, Montana 59405
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Prostate Cancer
524 reported clinical trials
2 medical researchers
Summary
Benefis Healthcare- Sletten Cancer Institute is a medical facility located in Great Falls, Montana. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Prostate Cancer and other specialties. Benefis Healthcare- Sletten Cancer Institute is involved with conducting 524 clinical trials across 518 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
John M. SchallenkampBillings Clinic Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Cancer
206 reported clinical trials
267 drugs studied
Benjamin T. MarchelloKalispell Regional Medical Center10 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
6 reported clinical trials
20 drugs studied
Clinical Trials running at Benefis Healthcare- Sletten Cancer Institute
Lung Cancer
Prostate Cancer
Breast Cancer
Bladder Cancer
Breast cancer
Ovarian Cancer
Pancreatic Cancer
Esophageal cancer
Cancer
Colorectal Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Benefis Healthcare- Sletten Cancer Institute?
Benefis Healthcare- Sletten Cancer Institute is a medical facility located in Great Falls, Montana. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Prostate Cancer and other specialties. Benefis Healthcare- Sletten Cancer Institute is involved with conducting 524 clinical trials across 518 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.
Where is Benefis Healthcare- Sletten Cancer Institute located?
**Sletten Cancer Institute**
- **Location:** 1117 29th Street South, Great Falls, MT 59405.
- **Accreditation:** Accredited by the American College of Surgeons Commission on Cancer since 1981.
- **Additional Facility:** Features a new Hi-Line Sletten Cancer Center in Havre, MT.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Benefis Healthcare- Sletten Cancer Institute, please call (406)455-5000. Detailed information on financial assistance, including eligibility and application processes, can be found on the Billing & Financial Assistance page of the Benefis Health System website.
What insurance does Benefis Healthcare- Sletten Cancer Institute accept?
**Benefis Sletten Cancer Institute Insurance and Partnerships**
- **Insurance Accepted:** Aetna Choice POS II, Aetna Elect Choice EPO Open Access, Aetna Innovation Health Aetna Premier Care Network Plus, Aetna Managed Care, Medicare, and Medicaid.
- **Services:** Offers cancer treatments and care to patients in central Montana.
- **Partnerships:** Has established partnerships with other healthcare providers to ensure comprehensive care for patients.
What awards or recognition has Benefis Healthcare- Sletten Cancer Institute received?
**Benefis Sletten Cancer Institute, Great Falls, Montana**
- Recognized by the American College of Surgeons Commission on Cancer for its accredited cancer program.
- Collaborates with the Montana Cancer Consortium, offering patients access to national clinical trials and enhancing research opportunities.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.